NCI Thesaurus OBO Edition
3770 terms(s) returned
| Term Type: | Record: 3701 to 3750 of 3770 Records | Page: 75 of 76, First Previous Next Last | Show Records Per Page |
- Ivuxolimab
- Ivy Incision Method
- Ixabepilone Regimen
- Ixazomib Regimen
- Ixekizumab
- Ixoberogene Soroparvovec
- Ixotatug Vedotin
- Izalontamab
- Izalontamab Brengitecan
- Izard County, AR
- Izastobart
- Izeltabart
- Izeltabart Tapatansine
- Izencitinib
- Izenivetmab
- Izilendustat
- Izokibep
- Izorlisib
- Izuforant
- Izumerogant
- Izuralimab
- iAPA-based Dendritic Cells/Cytotoxic T Lymphocytes
- iC9-GD2-CAR-CD28-OX40-expressing Autologous NKT Cells
- iC9-GD2-CD28-OX40-expressing T Lymphocytes
- iDworak et al Tumor Regression Grade (1997)
- iFGF23 Level Greater Than or Equal to 100 pg/mL
- iHealth COVID-19 Antigen Rapid Test
- iHealth Labs
- iNKT Cell Agonist ABX196
- iNOS Dimerization Inhibitor FK-330
- iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819
- iPSC-derived Anti-BCMA CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT576
- iPSC-derived Anti-CD19 CAR/CD16/IL-15RF/ADR-expressing CD38-eliminated NK Cells FT522
- iPSC-derived CD16-expressing Natural Killer Cells FT516
- iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596
- iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538
- iPSC-derived MSCs CYP-001
- iPSC-derived Natural Killer Cells FT500
- iRECIST Complete Response
- iRECIST Confirmed Progressive Disease
- iRECIST Partial Response
- iRECIST Stable Disease
- iRECIST Unconfirmed Progressive Disease
- id
- idic(X)(q13)
- in subset
- integrated Cancer Repository for Cancer Research
- interleukin-2/Monoclonal Antibody OKT3
- interleukin-2/Monoclonal Antibody OKT3/Tumor Necrosis Factor
- interleukin-2/Monoclonal Antibody OKT3/pentoxifylline
